GlobeNewswire·Nov 10, 2026, 7:30 AM ET

Exagen Inc. Reports Third Quarter 2026 Financial Results

Exagen Inc. reported third-quarter 2026 revenue of $18.4 million, a 7% increase from the same period in 2025.
Year-to-date revenue through September 30, 2026, grew 11% to $55.7 million.
Net loss for the third quarter narrowed to $6.3 million, a 12% reduction compared to $7.1 million in 2025.
Adjusted EBITDA loss for the nine months ended September 30, 2026, improved by over 30% to $4.2 million.
The trailing twelve-month average selling price (ASP) for AVISE CTD reached $451 per test, marking the 14th consecutive quarter of growth.
The company ended the quarter with $28.1 million in cash and cash equivalents.
Exagen presented nine abstracts at the 2026 American College of Rheumatology Convergence Conference, including analysis of over 375,000 tests.
The company reiterated full-year 2026 revenue guidance of $72 million to $75 million.
An educational webcast regarding myositis solutions is scheduled for December 15, 2026.
Exagen remains on track to launch its myositis offering in early 2027.
Operating expenses for the third quarter were $15.2 million, an increase from $13.2 million in 2025.
Gross margin for the third quarter was 58.8%, slightly up from 58.4% in 2025.